MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Auranofin

CAS No. : 34031-32-8

MCE 国际站：Auranofin

产品活性：Auranofin (SKF-39162)是硫氧还蛋白还原酶 (TrxR) 的抑制剂，IC₅₀为0.2 μM。Auranofin 表现出抗 SARS-CoV21 的抗病毒活性，对猴肾 Vero E6 细胞的 CC₅₀ 为 4.2 μM。

研究领域：Anti-infection

作用靶点：Bacterial  |  SARS-CoV

In Vitro: Auranofin is a drug that is approved for the treatment of rheumatoid arthritis but is being investigated for potential therapeutic application in a number of other diseases including cancer, neurodegenerative disorders. Auranofin induces apoptosis in cells through a Bax/Bak-dependent mechanism associated with selective disruption of mitochondrial redox homeostasis in conjunction with oxidation of Prx3.
Auranofin inhibits proliferation and survival of SKOV3 cells in a dose- and time-dependent manner. Auranofin treatment activates the pro-apoptotic caspase-3, increases protein levels of apoptosis-inducing proteins Bax and Bim and reduces the expression of the anti-apoptotic mediator Bcl-2 in SKOV3 cells.
Auranofin is a lipophilic gold compound with anti-inflammatory and immunosuppressive properties. Auranofin inhibits the cell growth and induction of mitochondrial apoptosis in PC3 human prostate cancer cells. Treatment with auranofin significantly inhibits cell viability with an IC₅₀ value of 2.5 μM after 24 h.

In Vivo: Prophylactic treatment of adjuvant-induced arthritis rats with auranofin results in a slight reduction in paw edema, a complete normalization of the depressed IL-2 production, and a reduction of the elevated IL-1 production, but has no effect on the depressed IL-3 production.

相关产品：Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Immunology/Inflammation Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Antibacterial Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Rare Diseases Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Off-patent Drug Library  |  Mitochondrial Toxicity Compound Library  |  Bioactive Compound Library Max  |  Rapamycin  |  Chloroquine  |  Dimethyl sulfoxide  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Dexamethasone  |  Staurosporine  |  Actinomycin D  |  Puromycin dihydrochloride  |  Etoposide  |  Brefeldin A  |  Nigericin sodium salt  |  CCCP  |  G-418 disulfate  |  Estradiol  |  5-Azacytidine  |  Thapsigargin  |  Hygromycin B  |  Mitomycin C  |  Ionomycin  |  Resveratrol  |  Tunicamycin  |  Lactate sodium  |  Everolimus  |  Doxycycline  |  Tacrolimus  |  Streptozotocin  |  Methotrexate  |  ALC-0315

热门产品线：重组蛋白  |  药物筛选  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。